Recap: Cytek Biosciences Q1 Earnings
Cytek Biosciences (NASDAQ:CTKB) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:03 PM. Here’s what…
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell
• Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 45.3% to $2.14 during Wednesday’s regular session. As of 13:30 EST,…
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $15
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $18 to $15.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 11.9% to $2.25 during Friday’s after-market session. The market value of their…
Goldman Sachs Maintains Buy on Cytek Biosciences, Lowers Price Target to $14
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and lowers the price target from $16 to $14.
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.
Earnings Outlook For Cytek Biosciences
Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that Cytek Biosciences will report an earnings per share (EPS) of $0.02.
Piper Sandler Maintains Overweight on Cytek Biosciences, Raises Price Target to $16
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $12 to $16.